HER2 expression in cervical cancer as a potential therapeutic target

BACKGROUND: Trastuzumab, a humanized monoclonal antibody against the HER2 receptor is currently being used in breast and other tumor types. Early studies have shown that a variable proportion of cervical carcinoma tumors overexpress the HER2 receptor as evaluated by diverse techniques and antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavez-Blanco, Alma, Perez-Sanchez, Victor, Gonzalez-Fierro, Aurora, Vela-Chavez, Teresa, Candelaria, Myrna, Cetina, Lucely, Vidal, Silvia, Dueñas-Gonzalez, Alfonso
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517717/
https://www.ncbi.nlm.nih.gov/pubmed/15341668
http://dx.doi.org/10.1186/1471-2407-4-59

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517717/
https://www.ncbi.nlm.nih.gov/pubmed/15341668
http://dx.doi.org/10.1186/1471-2407-4-59

Ejemplares similares